Adjuvant radiotherapy for ypN0 breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis
10.4174/astr.2025.109.5.286
- Author:
Hyung-Sik LEE
1
;
Sungmin KIM
;
Hyunjung KIM
;
Ki-Jung AHN
;
Hye Won PARK
;
Yunseon CHOI
Author Information
1. Department of Radiation Oncology, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Annals of Surgical Treatment and Research
2025;109(5):286-292
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study was performed to analyze whether adjuvant radiotherapy (RT) can improve the survival outcome for pathological node-negative (ypN0) breast cancer patients who underwent surgery after neoadjuvant chemotherapy (NAC).
Methods:In this meta-analysis, we reviewed papers related to adjuvant RT in ypN0 patients after NAC published between January 2010 and November 2024 using PubMed, EMBASE via Elsevier, Cochrane Library with keywords:“breast neoplasms,” “neoadjuvant therapy,” and “radiotherapy.” The effectiveness of post-mastectomy RT (PMRT) after mastectomy and regional nodal irradiation (RNI) after breast-conserving surgery (BCS) was evaluated. The end point of this study was overall survival (OS).
Results:We selected 11 retrospective papers for this meta-analysis out of 4,164 English full-text articles. There were 7 PMRT-related and 5 RNI-related papers (1 duplicated) for final analysis. Overall, PMRT in ypN0 patients improved OS (hazard ratio [HR], 0.862; 95% confidence interval [CI], 0.766–0.972; P = 0.015) after mastectomy. Moreover, OS (HR, 0.774;95% CI, 0.600–0.999; P = 0.049) was also improved by RNI for ypN0 patients after BCS.
Conclusion:For patients with ypN0 breast cancer who have undergone NAC and surgery, PMRT positively affected the survival outcome of patients. Therefore, it is necessary to undergo adjuvant RT to improve survival for ypN0 breast cancer patients.
